HIV AIDS infection in infants: Difference between revisions
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
The use of ART during pregnancy in HIV-infected women has resulted in a dramatic decrease in the transmission rate to infants, which is currently less than 2% in the United States, and the number of infants with AIDS in the United States continues to decline. | |||
==Recommendations== | ==Recommendations== | ||
===Diagnosis of HIV Infection in Infants=== | ===Diagnosis of HIV Infection in Infants=== | ||
Revision as of 13:46, 4 June 2012
|
AIDS Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV AIDS infection in infants On the Web |
|
American Roentgen Ray Society Images of HIV AIDS infection in infants |
|
Risk calculators and risk factors for HIV AIDS infection in infants |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The use of ART during pregnancy in HIV-infected women has resulted in a dramatic decrease in the transmission rate to infants, which is currently less than 2% in the United States, and the number of infants with AIDS in the United States continues to decline.
Recommendations
Diagnosis of HIV Infection in Infants
- Virologic assays that directly detect HIV must be used to diagnose HIV infection in infants younger than 18 months (AII). HIV antibody testing cannot establish HIV infection in this age group because maternal HIV antibodies may persist and interfere with the interpretation of a positive HIV antibody test.
- Virologic diagnostic testing is recommended in infants with known perinatal HIV exposure at ages 14–21 days, 1–2 months, and 4–6 months ( AII ).
- Virologic diagnostic testing at birth should be considered for infants at high risk of HIV infection (BIII).
- HIV DNA polymerase chain reaction (PCR) and HIV RNA assays are recommended as preferred virologic assays (AII).
- Confirmation of HIV infection should be based on two positive virologic tests obtained from separate blood samples (AI).
- Definitive exclusion of HIV infection (in the absence of breastfeeding) should be based on at least two negative virologic tests (one at >1 month and one at ≥4 months of age) (AII).
- Some experts confirm the absence of HIV infection at 12–18 months of age in infants with prior negative virologic tests by performing an antibody test to document loss of maternal HIV antibodies (BIII).
- In children ≥18 months of age, HIV antibody assays alone can be used for diagnosis (AII)
Laboratory Monitoring of Pediatric HIV Infection Before Initiation of Therapy
- The age of the child must be considered when interpreting the risk of disease progression based on CD4 percentage or count and plasma HIV RNA level (AII). For any given CD4 percentage or count, younger children, especially those in the first year of life, face higher risk of progression than do older children.
- In children younger than 5 years of age, CD4 percentage is preferred for monitoring immune status because of age-related changes in absolute CD4 count in this age group (AII).
- CD4 percentage or count should be measured at the time of diagnosis of HIV infection and at least every 3-4 months thereafter (AIII).
- Plasma HIV RNA should be measured to assess viral load at the time of diagnosis of HIV infection and at least every 3-4 months thereafter (AIII).
- More frequent CD4 cell and plasma HIV RNA monitoring should be considered in children with suspected clinical, immunologic, or virologic deterioration or to confirm an abnormal value (AIII).